Solid Start to 2025 with Revenue and EBITDA Growth
Sotera Health reported a 2.6% increase in total company revenues, or 4.4% on a constant currency basis, for Q1 2025 compared to Q1 2024. Adjusted EBITDA increased by 8.8%, or 11.2% on a constant currency basis.
Nelson Labs Margin Expansion
Nelson Labs achieved a 479 basis point margin expansion versus Q1 2024, marking the third consecutive quarter of year-over-year margin expansion.
Nordion's Strong Revenue Performance
Nordion's revenue increased by 36% to $33 million, or 40.6% on a constant currency basis, compared to Q1 2024. Segment income increased approximately 62%.
Reaffirmed 2025 Outlook
Sotera Health reaffirmed its 2025 outlook, expecting revenue growth in the range of 4% to 6% and adjusted EBITDA growth of 4.5% to 6.5% on a constant currency basis.
Successful Amendment to Revolving Credit Facility
The amendment added approximately $175 million in liquidity, extending maturity to April 2030.
FDA Clearance for Bionic Pancreas
Sotera Health played a critical role in securing FDA clearance for the first-ever bionic pancreas, showcasing the integrated expertise of Nelson Labs and Sterigenics.